COPD Clinical Trial and Studies

You can help researchers discover whether Ensifentrine or Itepekimabis are safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

Study To Assess The Efficacy, Safety, And Tolerability Of SAR440340/REGN/3500/ITEPEKIMAB In Chronic Obstructive Pulmonary Disease (AERIFY-1)

This is a study to evaluate the efficacy of Itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD (Chronic Obstructive Pulmonary Disease).

RPL554-CO-302: A Phase 3 Trial To Evaluate The Safety And Efficacy Of Ensifentrine In Patients With COPD

The purpose of this study is to determine if Ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

COPD Clinical Trial and Studies
tabs-image

Study Schedule

Study To Assess The Efficacy, Safety, And Tolerability Of SAR440340/REGN/3500/ITEPEKIMAB In Chronic Obstructive Pulmonary Disease (AERIFY-1)

Actual Study Start Date : December 16, 2020
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : May 2024

RPL554-CO-302: A Phase 3 Trial To Evaluate The Safety And Efficacy Of Ensifentrine In Patients With COPD

Actual Study Start Date : September 22, 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : February 2022

tabs-image

How to Join

Study To Assess The Efficacy, Safety, And Tolerability Of SAR440340/REGN/3500/ITEPEKIMAB In Chronic Obstructive Pulmonary Disease (AERIFY-1)

Carolina Clinical Research is currently seeking study participants 40 to 85 years of age with a current COPD diagnosis of at least one year, with a smoking history of greater than or equal to 10 years, but who are not currently smoking.

RPL554-CO-302: A Phase 3 Trial To Evaluate The Safety And Efficacy Of Ensifentrine In Patients With COPD

Carolina Clinical Research is currently seeking study participants 18 years and older with a current COPD diagnosis .

Join the study
tabs-image

More Information

Participation in this clinical study is voluntary and as such we would like you to go through as much information as possible.

With that in mind, click the button below or call (704) 290-4587

Learn more
tabs-image

With that in mind, click the button below or call (704) 290-4587

tabs-image

Research Center Location